Zheng Wu, Zheng Wang, Lei Zhang, Xiaojing Song. "Updated results from ALTER-H004 study: Anlotinib combined with TACE as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgery—A single arm, multi-center, phase II clinical trial.." Journal of Clinical Oncology, 2025. doi:10.1200/jco.2025.43.4_suppl.588